Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

INTRODUCTION: Combined treatment using anti‐programmed death‐ligand 1 antibody (anti‐PD‐L1) and platinum‐etoposide is the current standard first‐line treatment for patients with extensive‐stage (ES) small cell lung cancer (SCLC). However, the best treatment for relapsed ES‐SCLC after the first‐line...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomono, Hiromi, Taniguchi, Hirokazu, Fukuda, Minoru, Ikeda, Takaya, Nagashima, Seiji, Akagi, Kazumasa, Ono, Sawana, Umeyama, Yasuhiro, Shimada, Midori, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Hisamatsu, Yasushi, Morinaga, Ryotaro, Tagawa, Ryuta, Ogata, Ryosuke, Dotsu, Yosuke, Senju, Hiroaki, Soda, Hiroshi, Nakatomi, Katsumi, Hayashi, Fumiko, Sugasaki, Nanae, Kinoshita, Akitoshi, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542459/
https://www.ncbi.nlm.nih.gov/pubmed/37675546
http://dx.doi.org/10.1111/1759-7714.15097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542459/
https://www.ncbi.nlm.nih.gov/pubmed/37675546
http://dx.doi.org/10.1111/1759-7714.15097

Ejemplares similares